Wedbush Upgrades Mersana Therapeutics to Outperform, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst David Nierengarten upgraded Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Outperform and increased the price target from $2 to $7.
February 29, 2024 | 3:52 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush upgraded Mersana Therapeutics to Outperform and raised the price target from $2 to $7.
The upgrade from Neutral to Outperform by a reputable analyst, along with a significant increase in the price target, suggests a strong bullish outlook for Mersana Therapeutics. This is likely to positively influence investor sentiment and potentially lead to a short-term increase in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100